1921
Volume 29, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645
USD

Abstract

Abstract

Evaluation of the effectiveness of treatment of American cutaneous/mucocutaneous leishmaniasis is difficult because dramatic clinical improvement and apparent complete healing can be followed by delayed recurrence of lesions. The indirect fluorescent antibody test done with amastigote antigen was used to monitor treatment of 122 cases of cutaneous lesions and one patient with mucocutaneous disease. Clinical improvement and healing of lesions in many, but not all, cases was accompanied by a diminution of antibody titer, and in 10% of cases, by reversion to negativity. In two cases persistence of antibody in spite of healing was shown to be due to residual viable parasites which caused recurrence or new lesions. Further treatment brought about healing and reversion to seronegativity. The data suggest that successful treatment can be indicated by serologic response and, even in cases in which reversion to seronegativity does not occur, the relative reduction in serum antibody provides a basis for predicting recurrence of leishmanial lesions.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.1980.29.747
1980-09-01
2017-11-19
Loading full text...

Full text loading...

http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.1980.29.747
Loading
  • Accepted : 29 Mar 1980

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error